Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Oncologist ; 19(6): 602-7, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24760710

RESUMEN

Mutations in the IDH1 and IDH2 (isocitrate dehydrogenase) genes have been discovered across a range of solid-organ and hematologic malignancies, including acute myeloid leukemia, glioma, chondrosarcoma, and cholangiocarcinoma. An intriguing aspect of IDH-mutant tumors is the aberrant production and accumulation of the oncometabolite 2-hydroxyglutarate (2-HG), which may play a pivotal oncogenic role in these malignancies. We describe the first reported case of an IDH1 p.R132L mutation in a patient with hormone receptor-positive (HR+) breast adenocarcinoma. This patient was initially treated for locally advanced disease, but then suffered a relapse and metastasis, at which point an IDH1-R132 mutation was discovered in an affected lymph node. The mutation was subsequently found in the primary tumor tissue and all metastatic sites, but not in an uninvolved lymph node. In addition, the patient's serum and urine displayed marked elevations in the concentration of 2-HG, significantly higher than that measured in six other patients with metastatic HR+ breast carcinoma whose tumors were found to harbor wild-type IDH1. In summary, IDH1 mutations may impact a rare subgroup of patients with breast adenocarcinoma. This may suggest future avenues for disease monitoring through noninvasive measurement of 2-HG, as well as for the development and study of targeted therapies against the aberrant IDH1 enzyme.


Asunto(s)
Adenocarcinoma/genética , Neoplasias de la Mama/genética , Isocitrato Deshidrogenasa/genética , Neoplasias Hormono-Dependientes/genética , Adenocarcinoma/sangre , Adenocarcinoma/patología , Adenocarcinoma/orina , Neoplasias de la Mama/sangre , Neoplasias de la Mama/patología , Neoplasias de la Mama/orina , Femenino , Glutaratos/sangre , Glutaratos/orina , Humanos , Persona de Mediana Edad , Mutación , Neoplasias Hormono-Dependientes/sangre , Neoplasias Hormono-Dependientes/patología , Neoplasias Hormono-Dependientes/orina
2.
J Oncol Pract ; 8(5): e100-4, 2012 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-23277771

RESUMEN

PURPOSE: Multiple studies have shown that adherence to adjuvant hormonal therapy in women with breast cancer is suboptimal. Measurements of compliance with self-report, pill counts, and/or pharmacy records are susceptible to bias. We assessed the feasibility of using a urine anastrozole assay as an objective biomarker of nonadherence to anastrozole treatment. PATIENTS AND METHODS: We recruited consecutive postmenopausal women, age ≥ 18 years, with hormone-sensitive nonmetastatic breast cancer who were prescribed anastrozole at least 3 months before enrollment. Each completed a short survey to gather information on demographics, anastrozole compliance history, and self-reported medication history, tumor characteristics, and treatment received. A single, random 15-mL urine sample was collected and tested for the presence of anastrozole using a previously validated assay. Patients were told they were part of a study to determine if anastrozole could be detected in the urine. RESULTS: Among 96 participants, mean age was 63.7 years (range, 51 to 70 years). The population was diverse, with 56.5% white, 57.6% US born, 59.8% unemployed, and 56.6% college educated. Prior treatment included chemotherapy (50%) and/or radiotherapy (58.7%). Mean duration of anastrozole treatment was 2.2 years (standard deviation, 1.6). Four participants reported nonadherence and declined to submit urine samples, and two had no detectable level of anastrozole (six of 96; 6.3%). Detectable levels among adherent women ranged from 49.3 to 632.8 ng/mL. CONCLUSION: We demonstrated that collection of urine to measure anastrozole levels is feasible and reliable. Identifying biomarkers to measure adherence is critical for studies investigating interventions to improve hormonal therapy compliance.


Asunto(s)
Antineoplásicos Hormonales/orina , Neoplasias de la Mama/orina , Cumplimiento de la Medicación , Neoplasias Hormono-Dependientes/orina , Nitrilos/orina , Triazoles/orina , Anciano , Anastrozol , Antineoplásicos Hormonales/efectos adversos , Antineoplásicos Hormonales/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/patología , Femenino , Humanos , Persona de Mediana Edad , Neoplasias Hormono-Dependientes/tratamiento farmacológico , Neoplasias Hormono-Dependientes/patología , Nitrilos/uso terapéutico , Proyectos Piloto , Posmenopausia , Encuestas y Cuestionarios , Resultado del Tratamiento , Triazoles/uso terapéutico
3.
Klin Khir ; (8): 59-61, 2011 Aug.
Artículo en Ruso | MEDLINE | ID: mdl-22013693

RESUMEN

Last years while applying modern methods of topic diagnosis the adrenal glands tumors are revealed as an "incidental finding", so called "adrenal incidentalomas" (AI). It is necessary to investigate hormonal activity of these complaints for conduction of timely and radical treatment. The authors have analyzed of complaints, the objective and laboratory investigations data, which were conducted in 122 patients, suffering AI. The tumor hormonal activity identification constitutes one of indications for its surgical treatment.


Asunto(s)
Neoplasias de las Glándulas Suprarrenales/diagnóstico , Hallazgos Incidentales , Neoplasias Hormono-Dependientes/diagnóstico , Neoplasias de las Glándulas Suprarrenales/sangre , Neoplasias de las Glándulas Suprarrenales/orina , Adulto , Anciano , Anciano de 80 o más Años , Síndrome de Cushing/sangre , Síndrome de Cushing/diagnóstico , Síndrome de Cushing/orina , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neoplasias Hormono-Dependientes/sangre , Neoplasias Hormono-Dependientes/orina , Adulto Joven
4.
Prostate ; 71(6): 575-87, 2011 May.
Artículo en Inglés | MEDLINE | ID: mdl-20945500

RESUMEN

BACKGROUND: AGR2 is a member of the endoplasmatic reticulum protein disulphide isomerase gene family implicated in tumor metastasis. Its expression pattern, function, and utility as a marker remains to be further investigated. METHODS: Using real-time RT-PCR and immunohistochemistry, changes of expression in different tumor stages were explored in microdissected tumor samples. AGR2 transcript level in urine sediments was scrutinized for suitability as a tumor marker. AGR2 androgen regulation and function were analyzed in cellular prostate cancer models. RESULTS: AGR2 is highly expressed in prostate cancer compared to benign tissue in particular also in low-grade tumors and PIN lesions. AGR2 transcripts were detected in urine sediments of patients undergoing prostate biopsy with significantly higher levels in tumor patients. The urine AGR2/PSA transcript ratio allowed much better discrimination between cancer and benign patients than serum total PSA or %freePSA. Prostate tumor cells express and secrete variable amounts of AGR2 protein, the highest level was found in PC3 cells. In androgen receptor-positive cell lines AGR2 is upregulated by androgens. Increased expression enhanced the migratory and invasive potential but decreased growth and proliferation in vitro and in vivo. CONCLUSION: AGR2 enhances the invasion phenotype of prostate cancer cells while at the same time attenuating cell-cycle progression. This function, its expression pattern and the increased level of AGR transcripts in urine sediments of prostate cancer patients call for further exploration as a prostate cancer marker and a modulator of tumor growth and invasion.


Asunto(s)
Biomarcadores de Tumor/orina , Ciclo Celular/fisiología , Neoplasias Hormono-Dependientes/metabolismo , Neoplasias de la Próstata/metabolismo , Proteínas/metabolismo , Animales , Bioensayo , Biomarcadores de Tumor/biosíntesis , Biomarcadores de Tumor/genética , Ciclo Celular/genética , Estudios de Cohortes , Citometría de Flujo , Regulación de la Expresión Génica , Humanos , Masculino , Ratones , Ratones Desnudos , Mucoproteínas , Neoplasias Hormono-Dependientes/genética , Neoplasias Hormono-Dependientes/orina , Proteínas Oncogénicas , Neoplasias de la Próstata/genética , Neoplasias de la Próstata/orina , Proteínas/genética , ARN Neoplásico/biosíntesis , ARN Neoplásico/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Estadísticas no Paramétricas , Transcripción Genética , Transfección
5.
Ann Oncol ; 21(9): 1864-1869, 2010 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-20181574

RESUMEN

BACKGROUND: In patients with bone metastases from castration-resistant prostate cancer (CRPC) not pretreated with a bisphosphonate elevated N-telopeptide of type I collagen (uNTx), a marker of bone resorption, predicts skeletal-related events (SRE). The aim of this study was to assess the prognostic value of uNTx for overall survival (OS) and the incidence of SRE in patients with bone metastases from CRPC receiving zoledronic acid. METHODS: From 2004 to 2007, 94 patients with bone metastases from CRPC receiving zoledronic acid for at least 2 months were screened for uNTx. RESULTS: Median age was 66 years (range 46-88). Median serum prostate-specific antigen (PSA) was 66 ng/ml (0-3984) and median uNTx was 19 nmol/mM creatinine (3-489). During follow-up, 38 patients (40%) experienced an SRE. Median OS was 20 months [95% (CI) confidence interval 15-24). In the multivariate analysis, elevated uNTx [hazard ratio (HR) 2.2 (95% CI 1.2-4.0)], serum PSA [HR 2.8 (95% CI 1.6-5.1)], and ECOG performance status were the only independent prognostic factors for OS. Median OS was 12 months (10-16) and 25 months (21-34) in patients with uNTx > or =20 nmol/mM creatinine and in those with uNTx <20 nmol/mM creatinine, respectively. CONCLUSION: An elevated uNTx level is an independent prognostic factor for OS in patients with bone metastases from CRPC receiving a bisphosphonate.


Asunto(s)
Biomarcadores de Tumor/orina , Neoplasias Óseas/mortalidad , Colágeno Tipo I/orina , Neoplasias Hormono-Dependientes/mortalidad , Péptidos/orina , Neoplasias de la Próstata/mortalidad , Anciano , Anciano de 80 o más Años , Conservadores de la Densidad Ósea/uso terapéutico , Neoplasias Óseas/secundario , Neoplasias Óseas/orina , Castración , Difosfonatos/uso terapéutico , Estudios de Seguimiento , Humanos , Imidazoles/uso terapéutico , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Neoplasias Hormono-Dependientes/patología , Neoplasias Hormono-Dependientes/orina , Estudios Prospectivos , Antígeno Prostático Específico/sangre , Neoplasias de la Próstata/patología , Neoplasias de la Próstata/orina , Tasa de Supervivencia , Resultado del Tratamiento , Ácido Zoledrónico
6.
Environ Health Perspect ; 105 Suppl 3: 601-5, 1997 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-9168002

RESUMEN

The two main pathways for metabolizing estrogen are via 16alpha-hydroxylation and 2-hydroxylation. The 16alpha-hydroxy metabolites are biologically active; the 2-hydroxy metabolites are not. It is suggested that women who metabolize a larger proportion of their endogenous estrogen via the 16alpha-hydroxy pathway may be at significantly elevated risk of breast cancer compared with women who metabolize proportionally more estrogen via the 2-hydroxy pathway. In particular, it is suggested that the ratio of urinary 2-hydroxyestrone (2-OHE1) to 16alpha-hydroxyestrone (16alpha-OHE1) is an index of reduced breast cancer risk. This pilot study compared this ratio in postmenopausal women diagnosed with breast cancer to those of healthy controls. Urinary concentrations of estrone (E1), 17beta-estradiol (E2) and estriol (E3) were also quantified. White women who were subjects in a previous breast cancer case-control study at our institution were eligible for inclusion. All participants provided a sample of their first morning urine. The results from the first 25 cases and 23 controls are presented here. The ratio of 2-OHE1 to 16alpha-OHE1 was 12% lower in the cases (p=0.58). However, urinary E1 was 30% higher (p=0.10), E2 was 58% higher (p=0.07), E3 was 15% higher (p=0.48), and the sum of E1, E2, and E3 was 22% higher (p=0.16) in the cases. These preliminary results do not support the hypothesis that the ratio of the two hydroxylation metabolites (2-OHE1/16alpha-OHE1) is an important risk factor for breast cancer or that it is a better predictor of breast cancer risk than levels of E1, E2 and E3 measured in urine.


Asunto(s)
Neoplasias de la Mama/orina , Hidroxiestronas/orina , Neoplasias Hormono-Dependientes/orina , Neoplasias de la Mama/etiología , Estudios de Casos y Controles , Estradiol/orina , Estriol/orina , Estrona/orina , Femenino , Humanos , Menopausia , Persona de Mediana Edad , Neoplasias Hormono-Dependientes/etiología , Proyectos Piloto , Factores de Riesgo , Esteroide 16-alfa-Hidroxilasa
7.
Am J Clin Oncol ; 11 Suppl 2: S83-7, 1988.
Artículo en Inglés | MEDLINE | ID: mdl-3266542

RESUMEN

Fifty-four subjects were studied: 36 advanced prostatic adenocarcinoma patients in stage D and 18 normal age-matched male controls. Serum alkaline phosphatase, serum acid phosphatase, plasma osteocalcin, 24-h urinary hydroxyproline excretion, and 24-h whole-body retention of [99mTc]-methylene diphosphonate were measured in all subjects before and 3, 6, and 9 weeks after the start of treatment. Skeletal metastases were identified by radiography and/or [99mTc]-methylene diphosphonate bone scan. The results confirm that acid phosphatase is a significant marker in prostatic cancer; serum alkaline phosphatase may be useful in the evaluation and monitoring of bone metastases but it is not always specific; urinary excretion of hydroxyproline is an index of osteoclastic activity; serum osteocalcin may be considered more specific in the evaluation and monitoring of osteoblastic bone metastases in prostatic cancer.


Asunto(s)
Ácido 1-Carboxiglutámico/sangre , Biomarcadores de Tumor/sangre , Neoplasias Óseas/secundario , Proteínas de Unión al Calcio/sangre , Neoplasias de la Próstata/sangre , Vitamina K/sangre , Fosfatasa Ácida/sangre , Anciano , Anciano de 80 o más Años , Fosfatasa Alcalina/sangre , Neoplasias Óseas/diagnóstico por imagen , Huesos/análisis , Humanos , Hidroxiprolina/orina , Masculino , Persona de Mediana Edad , Neoplasias Hormono-Dependientes/sangre , Neoplasias Hormono-Dependientes/orina , Osteocalcina , Neoplasias de la Próstata/orina , Cintigrafía
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA